Pretransplant T-cell immune imbalance predicts slow engraftment after autologous hematopoietic stem cell transplantation in lymphoma

Table 2 Comparison of core immune and inflammatory indicators, peritransplant clinical events between early and slow engraftment groups in lymphoma patients undergoing autologous stem cell transplantation

Variable	Early engraftment group	Slow engraftment group	P value
CD8+ T cell (%), median (IQR, Q1-Q3)	41.68 (29.73-51.58)	47.47 (37.79-57.02)	0.0171,a
CD4+ T cell count (cells/μL), median (IQR, Q1-Q3)	315 (187-426.5)	234.37 (141.76-330.5)	0.0411,a
CD4/CD8 ratio, median (IQR, Q1-Q3)	0.95 (0.57-1.6)	0.79 (0.48-1.27)	0.0481,a
IL-2 (pg/mL), median (IQR, Q1-Q3)	0.74 (0.655-1.0275)	1.335 (0.8-1.75)	0.0031,a
IFN-γ (pg/mL), median (IQR, Q1-Q3)	1.275 (0.88-2.01)	2.715 (1.73-5.52)	0.0051,a
Days with fever during transplantation (days), median (IQR, Q1-Q3)	4 (2-8)	6 (3-11)	0.0061,a
Onset of neutropenia (days), median (IQR, Q1-Q3)	3 (2-4)	2 (1-4)	0.0331,a

¹Mann-Whitney U test.

^aP < 0.05.

All lymphocyte subsets and inflammatory factors were measured at pretransplant baseline. IQR: Interquartile range; IL-2: Interleukin-2; IFN-γ: Interferon-γ.